Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
|
02 April 2019 |
Forxiga approved in Japan for type-1 diabetes
|
27 March 2019 |
US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis
|
18 March 2019 |
Brilinta’s Phase III THEMIS trial met primary endpoint in
patients with established coronary artery disease and type-2 diabetes
|
25 February 2019 |
US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897
|
05 February 2019 |
Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
|
04 February 2019 |
AstraZeneca announces organisational changes
|
07 January 2019 |
Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer
|
27 December 2018 |
AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines
|
10 December 2018 |
AstraZeneca to divest US Synagis rights to Sobi
|
13 November 2018 |